K
Kirk Kozminski
Researcher at Pfizer
Publications - 5
Citations - 497
Kirk Kozminski is an academic researcher from Pfizer. The author has contributed to research in topics: Coronavirus & CA 15-3. The author has an hindex of 4, co-authored 5 publications receiving 169 citations. Previous affiliations of Kirk Kozminski include Ferring Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
Robert Louis Hoffman,Robert Steven Kania,Jay F. Davies,Rose Ann Ferre,Ketan S. Gajiwala,Mingying He,Robert J. Hogan,Kirk Kozminski,Lilian Y. Li,Jonathan W. Lockner,Jihong Lou,Michelle T. Marra,Lennert J. Mitchell,Brion W. Murray,James A. Nieman,Stephen Noell,Simon Paul Planken,Thomas Rowe,Kevin Ryan,George J. Smith,James Solowiej,Claire M. Steppan,Barbara Taggart +22 more
TL;DR: Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.
Posted ContentDOI
The Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
Robert M. Hoffman,Robert Steven Kania,Jay F. Davies,Rose Ann Ferre,Ketan S. Gajiwala,Mingying He,Robert J. Hogan,Kirk Kozminski,Lilian Y. Li,Jonathan W. Lockner,Jihong Lou,Michelle T. Marra,Mitchell Lennert J,Brion W. Murray,James A. Nieman,Stephen Noell,Simon Paul Planken,Thomas Rowe,Kevin M. Ryan,George J. Smith,James Solowiej,Claire M. Steppan,Barbara Taggart +22 more
TL;DR: Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.
Journal ArticleDOI
Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
Pei-Pei Kung,Ricardo Martinez,Zhou Zhu,Michael Zager,Alessandra Blasina,Isha Rymer,Jill Hallin,Meirong Xu,Christopher Carroll,John Chionis,Peter G. Wells,Kirk Kozminski,Jeffery Fan,Oivin Guicherit,Buwen Huang,Mei Cui,Chaoting Liu,Zhongdong Huang,Anand Sistla,Jennifer Yang,Brion W. Murray +20 more
TL;DR: Across a diverse panel of breast cell lines, CENP-E inhibition by PF-2771 selectively inhibits proliferation of basal breast cancer cell lines relative to premalignant ones and its response correlates with the degree of chromosomal instability.
Journal ArticleDOI
Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes
Michael Zager,Michael Zager,Kirk Kozminski,Kirk Kozminski,Bernadette Pascual,Kathleen M. Ogilvie,Shaoxian Sun +6 more
TL;DR: A mathematical model is presented that describes glucose modulation in an ob/ob mouse model via administration of a potent GK activator, with the goal of projecting a human efficacious dose and plasma exposure and the benefits of using such an approach in a drug discovery setting.